MorphoSys AG (LTS:0NDV)
€ 66.8 0 (0%) Market Cap: 2.55 Bil Enterprise Value: 2.50 Bil PE Ratio: 0 PB Ratio: 51.84 GF Score: 59/100

MorphoSys AG at JMP Securities Life Sciences Conference Transcript

Jun 16, 2022 / 01:30PM GMT
Release Date Price: €17.48 (-4.70%)
Jason Butler
JMP Group LLC - Analyst

We're going to go ahead and get started here. Thank you again for joining us this morning at the JMP Securities Life Science Conference. Excited to have MorphoSys and CEO Jean-Paul Kress. Jean-Paul, great to see you in person.

Jean;Paul Kress
MorphoSys AG - CEO

Thank you.

Questions & Answers

Jason Butler
JMP Group LLC - Analyst

There have been -- another exciting year for MorphoSys where you're continuing to execute on the launch of Monjuvi. You also have a late-stage pipeline, and some really exciting news in the last couple of days. So, maybe we start off with the most recent news, and that's -- you've out-licensed a couple of earlier-stage programs to HIBio. Can you just walk us through, I guess, the overall -- the transaction, but also your rationale for bringing on a partner for these programs?

Jean;Paul Kress
MorphoSys AG - CEO

Well, thank you, Jason, and good to see you in person.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot